Arch Therapeutics
1 Chieftain Lane
Natick
Massachusetts
01760
United States
Tel: 617-475-5254
Website: http://www.archtherapeutics.com/
153 articles about Arch Therapeutics
-
Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021Management to provide corporate update on Dermal Sciences and BioSurgery
3/2/2021
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), innovator of AC5 ® Advanced Wound System and other self-assembling Dermal Sciences and BioSurgery devices, announced today that it will be presenting at the H.C. Wainwright Global Life Sciences Conference, which will be held March 9-10, 2021.
-
Arch Therapeutics Announces Closing of $6.9 Million Private PlacementAC5® Advanced Wound System Commercialization Has Commenced
2/18/2021
Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced it has closed on the previously announced private placement of 43,125,004 shares of its common stock and warrants to purchase up to an aggregate of 32,343,753 shares of common stock,
-
Arch Therapeutics Announces $6.9 Million Private Placement
2/12/2021
Arch Therapeutics, Inc. announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $6.9 million through the issuance of an aggregate 43,125,002 shares of its common stock and warrants to purchase up to an aggregate of 32,343,751 shares of common stock, at a combined purchase price of $0.16 per share of common stock and associated warrant in a private placement.
-
Arch Therapeutics to Present at the H.C. Wainwright BioConnect Conference, January 11 - 14, 2021
1/5/2021
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced today that it will be presenting at the H.C. Wainwright BioConnect Conference, which will be held January 11-14, 2021. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Richard Davis, are scheduled to present via webcast, which will be available on-demand as of 6:00 AM
-
Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.Partnership provides US government facilities access and product distribution support
1/4/2021
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced today that it has entered into a distribution and sales administration agreement with Buffalo Supply, Inc. (“Buffalo Supply” or “BSI”) to be the exclusive distributor for products sold to United States government facilities worldwide. Buffalo Supply will place Arch products on their federal contr
-
Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference
12/11/2020
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced today that it will be presenting at the 13th annual LD Micro Main Event investor conference.
-
Arch Raises Approximately $1.1 Million with Convertible Note Issuance
11/10/2020
Arch Therapeutics, Inc., developer of novel self-assembling wound care and biosurgical devices, announces that it has raised approximately $1.1M from long-term shareholders.
-
Arch Therapeutics’ AC5 Advanced Wound System Presented at the 2020 Symposium on Advanced Wound Care (SAWC) Fall
11/9/2020
Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, highlights a series of clinical case reports and animal studies presented in abstract and poster formats at the 2020 Symposium on Advanced Wound Care (SAWC) Fall, which took place from November 4-6, 2020. The conference was hosted online due to the pandemic. Terrence W. Norchi, MD, President and CEO of Arch
-
Arch Therapeutics, Inc. to Present at the Virtual Investor KOL RoundtableLive moderated video webcast discussion of AC5 Advanced Wound System among management and Key Opinion Leaders on Wednesday, October 28th at 12:00 PM ET
10/22/2020
Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that management and key opinion leaders will discuss AC5 ® Advanced Wound System in the Virtual Investor KOL Roundtable on Wednesday, October 28, 2020 at 12:00 PM ET. For the Roundtable discussion, Terrence W. Norchi, MD, Chief Executive Officer of Arch will be joined by Randall Wolc
-
Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symposium on Advanced Wound Care (SAWC)
10/14/2020
Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that three clinical case reports and two animal studies of AC5 ® Advanced Wound System will be described in poster presentations at the upcoming 2020 Symposium on Advanced Wound Care (SAWC) Fall Virtual. The event will take place from November 4-6, 2020. AC5 Advanced Wound System recen
-
Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 12 PM ET
9/10/2020
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15 th , 2020 at 12:00 PM ET. The online conference is being held September 14-16, 2020. Dr. Norchi and Mr. Richard Davis, Chief Fi
-
Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday, September 1 at 1 PM ET
8/26/2020
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the LD 500 Virtual Conference on Tuesday, September 1st, 2020
-
Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedures was Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting
8/11/2020
Emerging technology presentation demonstrates use of AC5-GTM in submucosal lifting and management of gastrointestinal bleeding during porcine endoscopic procedures.
-
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Virtual 2020 Annual Meeting Starting August 11, 2020
8/7/2020
Emerging Technology video presentation describing swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection
-
Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat SeriesLive video moderated discussion with Dr. Terrence Norchi, CEO, on Monday, June 15, at 12:00 PM ET, immediately followed by an interactive Q&A session
6/8/2020
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the Virtual Investor Fireside Chat Series on Monday, June 15, 2020 at 12:00 PM ET.
-
Arch Raises $1.4 Million with Convertible Note Issuance and Warrant RepriceFinancing with long-term shareholders provides flexibility during product roll-out
6/5/2020
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, announces that it has raised $1.4M from long-term shareholders.
-
Arch Therapeutics to Provide Corporate Update at the Virtual Summer Summit
6/3/2020
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, will be featured as a presenting company at the Virtual Summer Summit. The conference is being held on June 9-12, 2020. Chief Executive Officer, Terrence W. Norchi, MD, is scheduled to provide a corporate update on Wednesday, June 10th at 1:35 PM ET. Dr. Norchi will be available for 1x1 virtual meetings with investors who
-
Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in EuropeNovel hemostatic wound dressing provides distinctive features
4/13/2020
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced receipt of the CE (Conformité Européenne) mark for its first-in-class would care product, AC5 TM Topical Hemostat (“AC5”). The CE mark provides authorization to commercialize AC5 in Europe as a dressing and to control bleeding in skin wounds in both out- and in-patient settings. Chi
-
Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain
3/23/2020
Arch Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) provided clearance to market AC5 ® Topical Gel that is manufactured using an additional supplier and additional manufacturing processes. AC5 Topical Gel is to be used in the management of partial and full-thickness wounds, such as pressu
-
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020
3/4/2020
Emerging Technology podium presentation to describe swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection